UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 201

Sortiert nach

P1209: PERIPHERAL BLOOD CTDNA-SEQUENCING ENABLES PREDICTION OF OUTCOMES IN PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA USING A DYNAMIC RISK MODEL

HemaSphere, 2023-08, Vol.7 (S3), p.e45690bd

2023

Volltextzugriff (PDF)

ABVD in Older Patients With Early-Stage Hodgkin Lymphoma Treated Within the German Hodgkin Study Group HD10 and HD11 Trials

Journal of clinical oncology, 2013-04, Vol.31 (12), p.1522-1529

2013

Volltextzugriff (PDF)

Behandlung des refraktären/rezidivierten Hodgkin-Lymphoms

InFo Hämatologie + Onkologie, 2019-10, Vol.22 (10), p.16-20

2019

Volltextzugriff (PDF)

Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma

Journal of clinical oncology, 2017-07, Vol.35 (19), p.2125-2132

2017

Volltextzugriff (PDF)

Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087

Blood, 2019-10, Vol.134 (14), p.1144-1153

2019

Volltextzugriff (PDF)

Neue Ansätze zur Behandlung des rezidivierten oder refraktären Hodgkin Lymphoms

Die Onkologie, 2022-10, Vol.28 (10), p.901-907

2022

Volltextzugriff (PDF)

Early report on the severity of COVID‐19 in hematologic patients infected with the SARS‐CoV2 omicron variant

European journal of haematology, 2022-10, Vol.109 (4), p.364-372

2022

Volltextzugriff (PDF)

Time‐dependent cost comparison and health economic impact analysis of second‐line interventions for transplant‐ineligible patients with relapsed or refractory diffuse large B cell lymphoma

European journal of haematology, 2024-09, Vol.113 (3), p.371-383

2024

Volltextzugriff (PDF)

Risk stratification and prognostic biomarkers in relapsed Hodgkin lymphoma

British journal of haematology, 2020-09, Vol.190 (6), p.813-814

2020

Volltextzugriff (PDF)

Leucocyte and eosinophil counts predict progression‐free survival in relapsed or refractory classical Hodgkin Lymphoma patients treated with PD1 inhibition

British journal of haematology, 2018-06, Vol.181 (6), p.837-840

2018

Volltextzugriff (PDF)

Cost‐effectiveness analysis of transplant‐ineligible relapsed or refractory diffuse large B‐cell lymphoma treatment options—Experience of the efficiency frontier approach

European journal of haematology, 2023-12, Vol.111 (6), p.895-908

2023

Volltextzugriff (PDF)

Non‐Hodgkin lymphoma after treatment for classical Hodgkin lymphoma: a report from the German Hodgkin Study Group

British journal of haematology, 2021-05, Vol.193 (3), p.515-519

2021

Volltextzugriff (PDF)

Fibroblast-Activation Protein PET and Histopathology in a Single-Center Database of 324 Patients and 21 Tumor Entities

Journal of Nuclear Medicine, 2023-05, Vol.64 (5), p.711-716

2023

Volltextzugriff (PDF)

Rezidiviertes oder refraktäres klassisches Hodgkin-Lymphom

Onkologie (Heidelberg, Germany), 2018-04, Vol.24 (4), p.322-328

2018

Volltextzugriff (PDF)

Treatment of relapsed and refractory Hodgkin Lymphoma

Seminars in hematology, 2016-07, Vol.53 (3), p.180-185

2016

Volltextzugriff (PDF)

Phase I study of domatinostat (4SC‐202), a class I histone deacetylase inhibitor in patients with advanced hematological malignancies

European journal of haematology, 2019-02, Vol.102 (2), p.163-173

2019

Volltextzugriff (PDF)

Low B‐cell content is associated with a CD73‐low tumour microenvironment and unfavourable prognosis in classic Hodgkin lymphoma

British journal of haematology, 2023-06, Vol.201 (6), p.1097-1102

2023

Volltextzugriff (PDF)

Dose-Intensification in Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial

Journal of clinical oncology, 2012-03, Vol.30 (9), p.907-913

2012

Volltextzugriff (PDF)

Clinical outcomes of relapsed and refractory Hodgkin lymphoma patients after contemporary first-line treatment: a German Hodgkin Study Group analysis

Leukemia, 2022-03, Vol.36 (3), p.772-780

2022

Volltextzugriff (PDF)

JAK inhibition with ruxolitinib in relapsed or refractory classical Hodgkin lymphoma: Final results of a phase II, open label, multicentre clinical trial (JeRiCHO)

European journal of haematology, 2022-12, Vol.109 (6), p.728-735

2022

Volltextzugriff (PDF)

1 – 25 von 201

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(196)
Mit Volltextzugriff
(173)

Publikationsform

Sprache

Englisch
(194)
Japanisch
(9)
Deutsch
(7)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(111)
Science & Technology
(111)
Humans
(86)
Hematology
(67)
Oncology
(54)
Male
(40)
Female
(39)
Middle Aged
(39)
Adult
(38)
Hodgkin Disease - Drug Therapy
(36)
Hodgkin Disease - Pathology
(30)
Lymphoma
(29)
Aged
(26)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(26)
Hodgkin Lymphoma
(26)
Young Adult
(25)
Hodgkin's Lymphoma
(20)
Treatment Outcome
(20)
Prognosis
(19)
Adolescent
(17)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

P1209: PERIPHERAL BLOOD CTDNA-SEQUENCING ENABLES PREDICTION OF OUTCOMES IN PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA USING A DYNAMIC RISK MODEL

ABVD in Older Patients With Early-Stage Hodgkin Lymphoma Treated Within the German Hodgkin Study Group HD10 and HD11 Trials

Behandlung des refraktären/rezidivierten Hodgkin-Lymphoms

Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma

Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087

Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial

Neue Ansätze zur Behandlung des rezidivierten oder refraktären Hodgkin Lymphoms

Early report on the severity of COVID‐19 in hematologic patients infected with the SARS‐CoV2 omicron variant

Time‐dependent cost comparison and health economic impact analysis of second‐line interventions for transplant‐ineligible patients with relapsed or refractory diffuse large B cell lymphoma

PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial

Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group

Risk stratification and prognostic biomarkers in relapsed Hodgkin lymphoma

Leucocyte and eosinophil counts predict progression‐free survival in relapsed or refractory classical Hodgkin Lymphoma patients treated with PD1 inhibition

Cost‐effectiveness analysis of transplant‐ineligible relapsed or refractory diffuse large B‐cell lymphoma treatment options—Experience of the efficiency frontier approach

Non‐Hodgkin lymphoma after treatment for classical Hodgkin lymphoma: a report from the German Hodgkin Study Group

Fibroblast-Activation Protein PET and Histopathology in a Single-Center Database of 324 Patients and 21 Tumor Entities

Rezidiviertes oder refraktäres klassisches Hodgkin-Lymphom

Treatment of relapsed and refractory Hodgkin Lymphoma

Phase I study of domatinostat (4SC‐202), a class I histone deacetylase inhibitor in patients with advanced hematological malignancies

Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group

Low B‐cell content is associated with a CD73‐low tumour microenvironment and unfavourable prognosis in classic Hodgkin lymphoma

Dose-Intensification in Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial

Clinical outcomes of relapsed and refractory Hodgkin lymphoma patients after contemporary first-line treatment: a German Hodgkin Study Group analysis

Reinduction therapy with everolimus in combination with dexamethasone, high‐dose cytarabin and cisplatinum in patients with relapsed or refractory classical Hodgkin lymphoma: an experimental phase I/II multicentre trial of the German Hodgkin Study Group (GHSG HD‐R3i)

JAK inhibition with ruxolitinib in relapsed or refractory classical Hodgkin lymphoma: Final results of a phase II, open label, multicentre clinical trial (JeRiCHO)

Suchergebnisse filtern